---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-22-000060"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2022-11-18T23:59:59+00:00"
generated_at: "2026-06-21T15:41:48.006498+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Amphastar subsidiary enters up to $1.5M supply deal with related party Letop Biotech

## Summary
- ANP subsidiary signed 3-year supply agreement with Nanjing Letop Biotechnology for chemical intermediates.
- Total cost capped at ~$1.5M over 3 years; no minimum purchase obligation for ANP.
- Henry Zhang, immediate family of CEO Jack Zhang and Chair Mary Luo, owns majority of Letop; deal was approved by independent Audit Committee members.
- ANP retains ownership of all confidential information shared with Letop under the agreement.
- Payments in Chinese yuan; price adjustments allowed once per 12 months with 2-month notice and customer consent.

## SEC filing metadata
- accession: 0001297184-22-000060
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2022-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000060/0001297184-22-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000060/amph-20221115x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-22-000060
- JSON: https://secwatch.observer/filing/0001297184-22-000060.json
- Plain text: https://secwatch.observer/filing/0001297184-22-000060.txt

## Key facts
- Material Agreements
  Amphastar Pharmaceuticals, Inc. entered into Agreement with Nanjing Letop Biotechnology Co., Ltd. valued at approximately $1.5 million (effective 2022-11-15).
  - Action: entry
  - Agreement: supply
  - Counterparty: Nanjing Letop Biotechnology Co., Ltd.
  - Value: approximately $1.5 million
  - Effective: 2022-11-15
  source text: On November 15, 2022 (the “Effective Date”) Amphastar Nanjing Pharmaceuticals, Inc. (“ANP”), a wholly owned subsidiary of Amphastar Pharmaceuticals, Inc. (the “Company”), entered into a supply agreement (the “Agreement”) with Nanjing Letop Biotechnology Co., Ltd. (“Letop”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000060/0001297184-22-000060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.